Skip to main content

Whole-genome sequencing for TB source investigations: principles of ethical precision public health

Buy Article:

$34.78 + tax (Refund Policy)

BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis allows rapid, accurate inferences about the sources, location and timing of transmission. However, in an era of heightened concern for personal privacy and science distrust, such inferences could result in unintended harm and undermine the public´s trust.

METHODS: We held interdisciplinary stakeholder discussions and performed ethical analyses of real-world illustrative cases to identify principles that optimise benefit and mitigate harm of M. tuberculosis WGS‐driven TB source investigations.

RESULTS: The speed and precision with which real‐time WGS can be used to associate M. tuberculosis strains with sensitive information has raised important concerns. While detailed understanding of transmission events could mitigate harm to vulnerable patients and communities when otherwise unfairly blamed for TB outbreaks, the precision of WGS can also identify transmission events resulting in social blame, fear, discrimination, individual or location stigma, and the use of defaming language by the public, politicians and scientists. Public health programmes should balance the need to safeguard privacy with public health goals, transparency and individual rights, including the right to know who infects whom or where.

CONCLUSIONS: Ethical challenges raised by real‐time WGS‐driven TB source investigation requires public health authorities to move beyond their current legal mandate and embrace transparency, privacy and community engagement.

Keywords: epidemiology; ethics; source investigation; tuberculosis; whole-genome sequencing

Document Type: Research Article

Affiliations: 1: Department of Family Medicine and Population Health, Faculty of Medicine, University of Antwerp, Antwerp, Belgium 2: Instituto de Investigación Sanitaria Gregorio Marañón, Madrid 3: School of Chemistry and Bioscience, University of Bradford, UK 4: Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO) Public Health Valencia, Valencia, Spain 5: Flemish Association of Respiratory Health and Tuberculosis Control, Antwerp, Belgium, Belgian Lung and Tuberculosis Association, Brussels, Belgium 6: National Reference Centre of Tuberculosis and Mycobacteria, Infectious Diseases in Humans, Sciensano, Brussels, Belgium 7: Belgian Lung and Tuberculosis Association, Brussels, Belgium 8: Joint Research Unit “Infection and Public Health” FISABIO/University of Valencia-I2SysBio and CIBER in Epidemiology and Public Health, Valencia, Spain 9: Agency for Care and Health, Government of Flanders, Brussels, Belgium 10: Department of Social Medicine, University of North Carolina at Chapel Hill, NC, USA

Publication date: 01 March 2021

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content